Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03239574 · ClinicalTrials.gov registry record
MightySat - Clinical Performance Comparison Study
A clinical trial, sponsored by Masimo Corporation.
- Completed
- Registry status
- 34
- Enrollment target
NCT03239574: Completed study, sponsored by Masimo Corporation.
NCT03239574 is a clinical trial that has completed, run by Masimo Corporation. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03239574 has completed, sponsored by Masimo Corporation.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
This study compares the performance of respiratory rate from pleth (RRp) measured with MightySat device on healthy subjects.Subjects will be asked to breathe at specific rates ranging from 5 to 30 breaths per minute.
Primary Outcome
Accuracy will be determined by comparing the noninvasive respiratory rate by pleth (RRp) measurement of the MightySat to the respiratory rate (RR) reference and calculating the arithmetic root mean square error (Arms) value. In order to obtain the Arms value, the RR measurement from the reference is subtracted from the MightySat RRp measurement for a number of samples, the average of this difference is computed as the bias. The standard deviation of the differences is computed as the precision.
Interventions
- DEVICE MightySat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2017-07-20 |
What the finished NCT03239574 record still lists
NCT03239574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MightySat is the first listed.
NCT03239574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03239574 about?
NCT03239574 is a clinical study titled "MightySat - Clinical Performance Comparison Study". This study compares the performance of respiratory rate from pleth (RRp) measured with MightySat device on healthy subjects.Subjects will be asked to breathe at specific rates ranging from 5 to 30 breaths per minute.
What is the current status of trial NCT03239574?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2017-07-10. Estimated completion is 2017-07-20.
What interventions are being tested in trial NCT03239574?
The interventions under investigation include: MightySat (DEVICE).
Who is sponsoring clinical trial NCT03239574?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI